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Cyclopentenone 15-deoxy-D
12,14-prostaglandin J2 (15d-PGJ2) exerts antineoplastic effects on various types of human cancer. We
recently showed that treatment with 15d-PGJ2 induces apoptosis accompanied by downregulation of the oncogenic signal transducer
and activator of transcription 3 (Stat3) signalling in human oral squamous cell carcinoma (SCC) cells. The current study examines the
effects of 15d-PGJ2 on the epidermal growth factor receptor (EGFR) and Janus Kinase (JAK)-mediated signalling pathways. Inhibition
of Stat3 by 15d-PGJ2 was abolished by exogenous stimulation with transforming growth factor alpha (TGF-a), but not interleukin 6
(IL-6), supporting a selective effect of 15d-PGJ2 on IL-6-mediated signalling. Importantly, 15d-PGJ2 selectively abrogated constitutive
and IL-6-mediated JAK phosphorylation without affecting EGFR-activated levels. Moreover, the inhibitory effect of 15d-PGJ2 on JAK
signalling required the reactive a,b-unsaturated carbon within the cyclopentenone ring. Targeting of JAK signalling using a specific JAK
inhibitor also abolished Stat3 phosphorylation and resulted in apoptosis in oral SCC cells. Our findings provide the first evidence for
15d-PGJ2–mediated downregulation of constitutive and IL-6-induced JAK signalling in cancer and support that JAK inhibition and
suppression of EGFR-independent Stat3 activation by 15d-PGJ2 represent a promising approach for induction of apoptosis in oral
SCC cells.
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Signal transducer and activator of transcription (STAT) proteins
are latent cytoplasmic transcription factors that typically become
activated in response to extracellular signals such as growth factors
and cytokines (Darnell Jr, 1997; Bromberg and Darnell Jr, 2000).
Upon binding to their corresponding cell membrane receptors,
cytokines and growth factors induce STAT tyrosine phosphoryla-
tion, mediated by cytokine receptor-associated tyrosine kinases
(i.e. Janus Kinase family members, including Jak1, Jak2, Jak3 and
Tyk2) and growth factor receptors with intrinsic kinase activity
(e.g. epidermal growth factor receptor, EGFR), respectively
(Darnell Jr, 1997; Bromberg and Darnell Jr, 2000). In addition,
the Src family of nonreceptor tyrosine kinases has also been shown
to phosphorylate STAT proteins (Bromberg and Darnell Jr, 2000).
Activated STAT molecules form homo- or heterodimers and
translocate to the nucleus, where they bind to the promoter region
of specific target genes, thus regulating their transcription (Darnell
Jr, 1997; Bromberg and Darnell Jr, 2000).
STATs have been identified as critical regulators of various
normal cellular processes (Darnell Jr, 1997; Levy, 1999). However,
persistent STAT activation has been convincingly implicated in
oncogenesis (Bowman et al, 2000; Bromberg and Darnell Jr, 2000;
Bromberg, 2001, 2002). It has been established that abnormal
activation of STAT molecules (especially involving Stat3 and Stat5)
stimulates cell proliferation and prevents apoptosis in a number of
human tumours, including leukaemia, multiple myeloma, breast,
prostate and non-small-cell lung cancer (Bromberg, 2002). There-
fore, disruption of aberrant STAT activation in tumours, which
typically depends on deregulation of specific upstream tyrosine
kinases, has been proposed as a valid molecular target for cancer
therapy (Bowman et al, 2000; Turkson and Jove, 2000; Bromberg,
2001, 2002; Buettner et al, 2002).
In head and neck squamous cell carcinoma (SCC), there is
evidence that Stat3 constitutive activation is linked to cancer
development and growth (Grandis et al, 2000; Song and Grandis,
2000; Kijima et al, 2002). Importantly, targeting of Stat3, through
transfection of dominant-negative constructs or application of
antisense oligonucleotide treatment, results in significant growth
inhibition (Grandis et al, 1998; Song and Grandis, 2000).
Furthermore, Stat3 antisense gene therapy leads to increased
tumour apoptosis in vivo, which is associated with decreased Bcl-
XL protein expression (Grandis et al, 2000; Song and Grandis,
2000; Kijima et al, 2002).
Cyclopentenone prostaglandins, especially 15-deoxy-D
12,14-
prostaglandin J2 (15d-PGJ2), have been shown to exert antineo-
plastic effects on various types of human cancer (Kim et al, 1993;
Ahn et al, 1998; Clay et al, 1999; Keelan et al, 1999; Butler et al,
2000; Chang and Szabo, 2000; Clay et al, 2001; Straus and Glass,
2001). These effects, frequently attributed to activation of
peroxisome proliferator-activated receptor gamma (PPARg), have
been recently proven to be at least partially mediated through
PPARg-independent pathways (Clay et al, 2001, 2002; Straus and
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recently demonstrated that 15d-PGJ2 inhibits cell growth and
induces apoptosis in oral SCC utilising PPARg-independent
mechanisms (Nikitakis et al, 2002). Moreover, we suggested that
the effects of 15d-PGJ2 on oral SCC cells may be related to its
ability to downregulate Stat3 (Nikitakis et al, 2002). In the present
study, we investigated the effect of 15d-PGJ2 on tyrosine kinases
that regulate growth and survival of oral SCC cells, including JAKs
and EGFR. Our results indicate that 15d-PGJ2 targets JAK
signalling independent of EGFR signalling and suggest that
inhibition of IL-6-mediated JAK signalling and suppression of
EGFR-independent Stat3 activation may represent a novel
therapeutic approach in oral cancer.
MATERIALS AND METHODS
Cell lines and cell culture
All experiments were performed using established human oral SCC
cell lines (SCC-4, -9, -15 and -25) obtained from American Type
Culture Collection (ATCC) (Manassas, VA, USA). Cells were
cultured in a 1:1 mixture of Ham’s F12 and Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% foetal bovine serum
(FBS), 100U of penicillin, 100mgml
1 streptomycin and
0.4mgml
1 hydrocortisone (Sigma Chemical Co., St Louis, MO,
USA) at 371C in a 5% CO2 air atmosphere. Cells were subcultured
by disaggregation with trypsin (0.1%)-EDTA (0.01%) in phos-
phate-buffered saline (PBS) at pH 7.5.
Western blot analysis
Cells were plated in six-well plates at 5x10
4cellswell
1 and were
allowed to grow to 80% confluency. A measure of 10, 20 or 40mM
15d-PGJ2 (Cayman Chemical, Ann Arbor, MI, USA) dissolved in
100% DMSO, 50mM AG490 (Calbiochem, San Diego, CA, USA)
dissolved in 100% DMSO, 100nM PD153035 (Calbiochem), 20 or
40mM 9,10-dihydro-15-Deoxy-D
12,14-PGJ2 (CAY10410) (Cayman
Chemical) dissolved in 100% DMSO, 20ngml
1 rIL-6 (Calbio-
chem) or 25ngml
1 TGF-a (Calbiochem) was added to normal
medium (NM). The final concentration of DMSO did not exceed
0.1%. Alternatively, cells were pretreated with 15d-PGJ2 for 1h and
subsequently treated with rIL-6 or TGF-a. Following incubation for
various time periods, the cells were washed twice with cold PBS,
lysed in RIPA buffer (50mM Tris (pH 7.4), 150mM NaCl, 1% Triton
X-100, 1% deoxycholic acid, sodium salt, 0.1% sodium dodecyl
sulphate (SDS), 100mgml
1 phenylmethylsulphonyl fluoride,
1mgml
1 aprotinin, 1mM dithiothreitol and 1mM sodium
orthovanadate) for 10min, and scraped. The extracts were centri-
fuged at 40000g for 15min at 41C. Protein concentrations were
measured and equalised using Bio-Rad protein assay (Bio-Rad
Laboratories, Richmond, CA, USA) according to the manufac-
turer’s instructions.
Western blot analysis was performed using phospho-Stat3
(Tyr705) antibody (1:500) (Cell Signaling Technology, Beverly,
MA, USA), phospho-Jak2 (Tyr1007, Tyr1008) antibody (0.5mgml
1)
(Upstate Biotechnology, Lake Placid, NY, USA) or SOCS3 (M-20)
antibody (1:200) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
according to the manufacturer’s instructions. Blots were stripped
(20mM dithiothreitol, 2% SDS and 67.5mM Tris-HCl (pH 6.7)) and
then reprobed with Stat3 antibody (1:1000) (Cell Signaling
Technology), Jak2 antibody (1:1000) (Upstate Biotechnology) or
b-actin antibody (Sigma-Aldrich, St Louis, MO, USA), respectively.
Immunoprecipitation
Cells (510
4well
1) were allowed to grow to 80% confluency and
rIL-6 was added to normal medium at 25ngml
1 concentration.
Alternatively, cells were treated with 20mM 15d-PGJ2,4 0 mM
CAY10410 or 50mM AG490, dissolved in 100% DMSO. Cells were
also pretreated with 15d-PGJ2 and subsequently treated with rIL-6.
The final concentration of DMSO did not exceed 0.1%. Following
incubation for various time periods, the cells were lysed in RIPA
buffer as described above. Immunoprecipitation of Jak1, Jak2,
EGFR and SHP2 were performed using 1mg of whole cell lysate.
Jak1 antibody (4mgml
1) (Upstate Biotechnology, Lake Placid,
NY, USA), EGFR antibody (1:100) (Cell Signaling Technology) or
SHP2 (5mgml
1) (BD Biosciences Pharmingen, San Diego, CA,
USA) were added to the precleared supernatant and incubated
overnight at 41C. Lysates were then incubated with protein A
magnetic beads (New England Biolabs, Beverly, MA, USA) for 2h.
Beads were washed and resuspended in sample loading buffer
(187.5mM Tris-HCl (pH 6.8), 6% (wv
1) SDS, 30% glycerol,
150mM DTT, 0.03% (wv
1) bromophenol blue and 2% b-
mercaptoethanol). Western blot analysis was performed using
phospho-tyrosine-specific monoclonal antibody 4G10 (1mgml
1)
(Upstate Biotechnology). Membranes were reprobed with Jak1
(1:1000), EGFR (1:1000) or SHP2 (1:2500) antibodies as controls.
Cell growth inhibition
Cells were plated at 510
4cellswell
1 in 24-well plates containing
normal growth medium. After 24h, DMSO at 0.1% or AG490 at 25,
50 or 100mM was added. The final concentration of DMSO did not
exceed 0.1%. Following incubation for 24, 48 or 72h, cells were
enzymatically removed and counted using a Coulter Counter
(Coulter Model ZI, Coulter Corporation, Miami, FL, USA). All
analyses were performed in triplicate.
Measurement of apoptosis
Cells were treated with either 0.1%. DMSO or AG490 at 50 or
100mm for 48h. Cells were washed twice with cold PBS and
resuspended in 1 binding buffer. Early apoptotic changes were
identified by Annexin V-FITC and PI staining (BD Biosciences).
The extent of apoptosis was assessed by relative fluorescence
intensity using a FACScan and Cell Quest software (Becton
Dickenson) as described (Nikitakis et al, 2002). All analyses were
performed in duplicate.
Statistical analysis
A two-way analysis of variance (ANOVA) test and Tukey test were
used to assess the presence of statistically significant differences
between groups (SigmaStat 3.0, SPSS Inc, Chicago, IL, USA);
Pp0.05 was considered statistically significant.
RESULTS
Inhibition of IL-6-mediated Stat3 phosphorylation by
cyclopentenone prostaglandin 15d-PGJ2.
In our previous study, we reported that treatment with 15d-PGJ2
(20mM) suppresses the levels of constitutively phosphorylated Stat3
(Nikitakis et al, 2002). To assess if 15d-PGJ2 modulates upstream
signalling leading to Stat3 repression, we tested the effect of 15d-
PGJ2 on IL-6-mediated Stat3 phosphorylation. In the absence of
pretreatment with 15d-PGJ2, IL-6 stimulation induced Stat3
phosphorylation (Figure 1A). However, in the presence of 10mM
15d-PGJ2, IL-6-induced Stat3 tyrosine phosphorylation was
attenuated as early as 45min. Pretreatment with 20 or 40mM
15d-PGJ2 resulted in further reduction of IL-6-stimulated Stat3
phosphorylation (Figure 1B). This decrease in Stat3 tyrosine
phosphorylation could not be attributed to a reduction in total
cellular Stat3 levels, which remained stable despite the various
treatments (or combinations thereof).
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It is well established that members of the JAK family of kinases
play an essential role in transducing signals from IL-6 type family
of receptors to downstream effectors including STATs (Heinrich
et al, 2003). In order to test the possibility that JAKs contribute to
aberrant Stat3 activity in oral SCC cells, we examined the effect of
AG490, a selective JAK inhibitor (Meydan et al, 1996; Nielsen et al,
1997), on Stat3 phosphorylation. AG490 (50mM) inhibited con-
stitutive Stat3 phosphorylation during treatment for up to 24h
(Figure 1C). Moreover, treatment with the EGFR ligand, TGF-a
(25ngml
1), reversed the AG490-mediated Stat3 repression
(Figure 1D), while 100nM treatment with a selective EGFR
inhibitor, PD153035, abolished TGF-a-mediated Stat3 phosphor-
ylation. (Figure 1E).
Given our finding that JAK inhibition can repress aberrant
Stat3 signalling in oral SCC, we assessed the effect of 15d-PGJ2 on
the induction of JAK phosphorylation. When SCC cells were
pretreated with 15d-PGJ2 (20mM), a time-dependent reduction of
IL-6-induced Jak1 phosphorylation was observed (Figure 2A).
Similarly, treatment with 15d-PGJ2 (20mM) abrogated Jak2
phosphorylation even in the presence of exogenous IL-6 for
10min (Figure 2A). Total Jak1 and Jak2 protein levels remained
unchanged following either treatment, indicating a specific effect
of 15d-PGJ2 on JAK phosphorylation. In addition, treatment with
15d-PGJ2 (20mM) inhibited Jak2 constitutive phosphorylation after
10min (Figure 2B). Similarly, AG490 (50mM) reduced constitutive
Jak2 phosphorylation levels as early as 10min of treatment
(Figure 2C). Interestingly, treatment with AG490 for 10min also
partially inhibited constitutive Jak1 phosphorylation (Figure 4B).
15d-PGJ2 does not inhibit EGFR-mediated Stat3 signalling
Given that autocrine and paracrine activation of the EGFR
signalling pathway by TGF-a has been linked to Stat3 activation
in head and neck SCC cells (Grandis et al, 2000; Song and Grandis,
2000), the possible involvement of EGFR activity in the inhibitory
effect of 15d-PGJ2 on Stat3 was examined. To assess the effect of
15d-PGJ2 on EGFR-mediated activation of Stat3, oral SCC cells
were stimulated with exogenous TGF-a in the presence or absence
of 15d-PGJ2. Pretreatment with 15d-PGJ2 (20mM) failed to inhibit
Figure 1 15d-PGJ2 inhibits IL-6-induced Stat3 phosphorylation in oral
SCC cells. (A) Oral SCC cells were treated with normal medium (NM) or
rIL-6 (20ngml
1) for 24h. (B) Oral SCC25 cells were treated with NM,
15d-PGJ2 (PG 10mM) for 1h or rIL-6 (20ngml
1) for 45min. Alternatively,
cells were treated rIL-6 (20ngml
1) for 45min in the presence of 10, 20 or
40mM pretreatment with 15d-PGJ2.( C) AG490 inhibits Stat3 constitutive
phosphorylation. Oral SCC9 cells were treated with either 0.1% DMSO as
vehicle (V) or AG490 (50mM) for 45min, 3, 6, 12 or 24h. (D and E) Oral
SCC9 cells were either untreated or supplemented with 25ngml
1 TGF-a
for 45min in the presence or absence of 1h pretreatment with (D),
AG490 (50mM)o r( E) PD153035 (100ngml
1). Cell lysates were blotted
with phospho-Stat3 antibody (Y705) and subsequently stripped and
reprobed with Stat3 antibody. Comparable results were obtained from
other cell lines used.
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Figure 2 15d-PGJ2 abrogates JAK phosphorylation in oral SCC cells. (A)
15d-PGJ2 abrogates IL-6-induced JAK phosphorylation in oral SCC cells.
Oral SCC25 cells were treated with NM, or rIL-6 (25ngml
1) for 5 or
10min in the presence or absence of pretreatment with 15d-PGJ2 (20mM)
for 30min, followed by immunoprecipitation for Jak1 and Western blotting
for phosphorylated (PY) and total Jak1. For Jak2, cell lysates were blotted
with phospho-Jak2 (Y1007, Y1008) antibody and subsequently stripped
and reprobed with Jak2 antibody. (B) 15d-PGJ2 inhibits constitutive JAK
phosphorylation in oral SCC cells. Oral SCC9 cells were either untreated
or treated with 15d-PGJ2 (20mM) for 5min, 10min, 20min, 30min and 1h.
(C) Effect of AG490 on constitutive JAK phosphorylation in oral SCC cells.
Oral SCC9 cells were either untreated or treated with AG490 (50mM) for
5min, 10min, 20min, 30min and 1h. In (B) and (C), cell lysates were
blotted with phospho-Jak2 (Y1007, Y1008) antibody and subsequently
stripped and reprobed with Jak2 antibody.
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(Figure 3A). Moreover, in the presence of 15d-PGJ2, down-
regulation of EGFR constitutive phosphorylation was not ob-
served. On the contrary, a slight increase in EGFR constitutive
phosphorylation was apparent following 15d-PGJ2 treatment
(Figure 3B).
Cyclopentenone structural requirement for the
inactivation of JAK and Stat3 by 15d-PGJ2
Because PPARg activation is insufficient to drive the Stat3
inhibitory effects of 15d-PGJ2 in oral SCC cells (Nikitakis et al,
2002), we tested the possibility that specific downmodulation of
JAK and Stat3 activation following treatment with 15d-PGJ2
requires the reactive electrophilic a,b-unsaturated carbonyl group
within the cyclopentenone ring. This electrophilic carbon can react
covalently with a number of nucleophiles, such as cysteine residues
in cellular proteins, glutathione or sulphhydryls producing
Michael addition-type reactions (Straus and Glass, 2001). Strik-
ingly, treatment of oral SCC cells with 9,10-dihydro-15-Deoxy-
D
12,14-PGJ2 (CAY10410), a structurally modified 15d-PGJ2 that
lacks the a,b-unsaturated carbonyl (Figure 4A), failed to inhibit
Jak1 (Figure 4B) and Stat3 (Figure 4C) constitutive phosphoryla-
tion levels. In contrast, in the presence of a reactive cyclopente-
none ring system, 15d-PGJ2 maintained a potent inhibitory effect
on JAK (Figure 4B) and Stat3 (Figure 4C) constitutive phosphory-
lation.
AG490 induces growth inhibition and apoptosis in oral
SCC cells
In order to determine the physiologic consequence of JAK
inhibition in oral SCC cells, cells were treated with a selective
JAK inhibitor. Treatment with AG490 resulted in a significant
(Pp0.05) dose-dependent and time-dependent growth reduction
in SCC cells (Figure 5A). In addition, analysis of cells treated with
AG490 by Annexin V-FITC and propidium iodide staining
revealed the AG490-induced cell growth inhibition resulted in a
dose-dependent increase in apoptosis (Figure 5B). Moreover, the
antineoplastic effects of AG490 in oral SCC cells also correlated
with the abrogation of Stat3 constitutive phosphorylation at 24, 48
and 72h (Figure 5C).
Effect of 15d-PGJ2 on negative regulators of Stat3
signalling
Because negative regulators of STAT signalling, including sup-
pressors of cytokine signalling (SOCS) and Src homology 2
domain-containing protein phosphatases (SHPs), may contribute
to the 15d-PGJ2-mediated repression of JAK and Stat3 phosphor-
ylation, the effect of 15d-PGJ2 on SOCS3 expression and SHP2
activity was examined. SOCS proteins are transcriptional targets of
STATs and function in a classic negative feedback loop to inhibit
further STAT activation by interacting with either JAK catalytic
or receptor sites (Starr and Hilton, 1998, 1999). In this regard,
treatment with IL-6 for 1h potently induced SOCS3 protein
levels in oral SCC cells (Figure 6A). In contrast, treatment with
15d-PGJ2 (20mM) for 1h did not have an effect on SOCS3 protein
expression (Figure 6A). Moreover, we assessed the effect of
15d-PGJ2 on SHP2 phosphorylation. Treatment with 15d-PGJ2
(20mM) for 10min did not upregulate SHP2 phosphorylation in
oral SCC cells (Figure 6B).
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Figure 3 Effect of 15d-PGJ2 on EGFR-mediated Stat3 signalling. (A)
Representative oral SCC cells (SCC9 and SCC25) were treated with NM,
15d-PGJ2 (20mM) for 45min, or stimulated with TGF-a (25ngml
1) for
45min in the presence or absence of 1h pretreatment with 15d-PGJ2 PG
(20mM). Cells were blotted with phospho-Stat3 antibody (Y705) and
subsequently stripped and reprobed with Stat3 antibody. (B) Representa-
tive oral SCC cells (SCC9 and SCC25) were treated with NM or 15d-PGJ2
PG (20mM) for 10min. EGFR constitutive phosphorylation was determined
by immunoprecipitation with EGFR antibody and Western blotting for
phosphorylated (PY) and total EGFR.
CAY10410
15d-PGJ2
COOH
COOH
O
O
NM
NM
PG
PStat3
Stat3
CAY10410
(20  M) (20  M) (40  M)
CAY10410
PY
Jak1
IP : Jak1
AG490 PG CAY10410
A
B
C
Figure 4 15d-PGJ2-mediated inhibition of JAK/Stat3 signalling requires
the reactive cyclopentenone ring system. (A) Structure of 9,10-dihydro-15-
Deoxy-D
12,14-PGJ2 (CAY10410) and 15d-PGJ2.( B) 15d-PGJ2, but not
CAY10410, abrogates constitutive JAK phosphorylation in oral SCC cells.
Oral SCC9 cells were treated with NM, AG490 (50mM), 15d-PGJ2 (20mM)
or CAY10410 (40mM) for 10min. Cell lysates were immunoprecipitated
with Jak1 antibody and Western blotted for phosphorylated (PY) and total
Jak1. (C) Effect of CAY10410 on Stat3 phosphorylation. Oral SCC9 cells
were treated with NM, 15d-PGJ2 (20mM) or CAY10410 (20 and 40mM) for
45min. Cells were blotted with phospho-Stat3 antibody (Y705) and
subsequently stripped and reprobed with Stat3 antibody.
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In an attempt to pinpoint the molecular target of 15d-PGJ2 in oral
SCC, we examined the effect of 15d-PGJ2 on critical regulators of
the Stat3 signalling complex, including the IL-6/JAK and the TGF-
a/EGFR pathways. Induction of these two signalling pathways with
exogenous ligands had opposite effects on 15d-PGJ2 activity in that
only TGF-a, but not IL-6, stimulation could reverse 15d-PGJ2-
induced Stat3 downregulation. Moreover, 15d-PGJ2 attenuated JAK
phosphorylation in the presence or absence of IL-6 treatment,
while modestly increased EGFR constitutively phosphorylated
levels. It is noteworthy that the downmodulation of both Jak1 and
Jak2 by 15d-PGJ2 preceded the inhibitory effects on IL-6-mediated
Stat3 activation. Based on these observations, we suggest that the
preferential target of 15d-PGJ2 is the IL-6/JAK signalling pathway,
of which downmodulation results in the inhibition of Stat3
activation and induction of apoptosis.
Stat3 constitutive activation has been previously linked to
aberrant TGF-a/EGFR autocrine or paracrine stimulation in head
and neck SCC (Grandis et al, 2000; Song and Grandis, 2000; Leong
et al, 2002). However, recent evidence points to the contribution of
Src in EGFR-mediated Stat3 activation (Xi et al, 2003) and
supports the existence of EGFR-independent Stat3 oncogenic
properties (Kijima et al, 2002). Moreover, head and neck and oral
SCC cells express a number of proinflammatory and proangiogenic
cytokines, including IL-6, which may participate in Stat3 activation
through binding to cytokine receptors and activation of receptor-
associated JAK molecules (Chen et al, 1998, 1999; Ondrey et al,
1999). The recent observation that IL-6 stimulation of the gp130
results in constitutive activation of Stat3 independently of EGFR in
head and neck SCC cells is also of particular importance
(Sriuranpong et al, 2003). In this regard, we suggest that JAKs
may serve a novel molecular target in oral SCC cells. This
hypothesis is further corroborated by our findings that targeting of
JAK activity by the specific kinase inhibitor AG490 abrogates
constitutive Stat3 activation and induces growth inhibition
accompanied by apoptotic cell death in oral SCC cells.
In that JAKs play an essential role in driving oncogenic Stat3
signalling (De Vos et al, 2000; Ni et al, 2000; Zhang et al, 2000; Li
and Shaw, 2002; Rane and Reddy, 2002), the ability of 15d-PGJ2 to
downmodulate IL-6/JAK signalling may also in part, explain the
antineoplastic properties of this agent against other types of
human cancer. For example, 15d-PGJ2 has been shown to have
potent PPARg-independent proapoptotic effects on breast cancer
cells (Clay et al, 2001, 2002), which exhibit constitutive Stat3
activation linked to cooperative activity of Src and JAK family
tyrosine kinases (Garcia et al, 2001).
Further investigations should focus on elucidating the mechan-
isms by which 15d-PGJ2 inhibits JAK. The fact that exogenous
stimulation with IL-6 was unable to reverse 15d-PGJ2-mediated
JAK inhibition suggests that the target of 15d-PGJ2 effects is the
kinase, but not the ligand. Consistent with this view, we have not
observed downregulation of IL-6 levels after treatment with 15d-
PGJ2 (unpublished data). Instead, JAK inhibition may be the result
of direct interaction between 15d-PGJ2 and JAK, especially
considering the ability of 15d-PGJ2molecules to bind to and
modify specific proteins through their reactive a,b-unsaturated
carbonyl group within the cyclopentenone ring (Straus and Glass,
2001). In view of the latter, our data highlighting the requirement
of the reactive cyclopentenone ring system for 15d-PGJ2-mediated
repression of JAK and Stat3 constitutive phosphorylation are of
particular importance. Moreover, 15d-PGJ2 possesses the ability to
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Figure 5 AG490 reduces cell growth and induces apoptosis in oral SCC
cells. (A) Oral SCC9 and SCC25 cells were treated with vehicle (0.1%
DMSO) or AG490 at 25, 50 and 100mM and cell growth was assessed
following 24, 48 and 72h of treatment using a Coulter Counter. Data are
expressed as mean values7s.d. for representative cells. There was a
significant growth inhibitory effect of AG490 (Pp0.05) with respect to
both dose and time using a two-way analysis of variance (ANOVA) test
and Tukey test. (B) Representative oral SCC cells (SCC25) were treated
with vehicle (0.1% DMSO) or AG490 at 50mM, and 100mM for 48h.
Annexin V-FITC assay revealed induction of apoptosis in cells treated with
AG490 compared to vehicle. (C) Oral SCC9 cells were treated with
vehicle (0.1% DMSO) or AG490 at 100mM and Stat3 constitutive
phosphorylation was assessed following 24, 48 and 72h of treatment.
Cells were blotted with phospho-Stat3 antibody (Y705) and subsequently
stripped and reprobed with Stat3 antibody.
SOCS3
Actin
NM
NM
PY
SHP2
PG
PG IL-6 A
B
Figure 6 Effect of 15d-PGJ2 on negative regulators of Stat3 signalling.
(A) Effect of 15d-PGJ2 on SOCS3 expression. SCC9 cells were either
treated with 20mM, 15d-PGJ2 (PG) or rIL-6 (25ngml
1) for 1h. Cells were
blotted with SOCS3 (M-20) antibody and subsequently stripped and
reprobed with actin control antibody. (B) Effect of 15d-PGJ2 on SHP2
phosphorylation. SCC9 cells were treated with 20mM, 15d-PGJ2 (PG) for
10min. Cell lysates were immunoprecipitated with SHP2 antibody and
Western blotted for phosphorylated (PY) and total SHP2.
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contribute to the biological activities of cyclopentenone prosta-
glandins, including cytotoxic effects of 15d-PGJ2 (Kondo et al,
2001; Li et al, 2001; Lennon et al, 2002). The possible involvement
of redox-sensitive mechanisms in the function of 15d-PGJ2 as an
antineoplastic agent that induces cell growth inhibition and IL-6/
JAK/Stat3 suppression in oral SCC cells is currently under
investigation.
Alternatively, 15d-PGJ2, directly or through production of other
mediators, may induce negative regulators of JAK activity, such as
SOCS or SHP2. In this respect, stimulation with 15d-PGJ2 has been
shown to induce the transcription of SOCS1 and SOCS3 and to
activate SHP2, which in turn suppress inflammatory interferon
signalling mediated by the JAK/STAT pathway in primary
astrocytes (Park et al, 2003). However, we did not observe
upregulation of SOCS3 and SHP2 during 15d-PGJ2-mediated
repression of JAK phosphorylation in oral SCC cells. Although
our findings suggest that the inhibition of JAK/STAT signalling by
15d-PGJ2 may require other mechanisms in oral SCC cells, the
possible involvement of other negative regulators of JAK activity
(Starr and Hilton, 1998; Starr and Hilton, 1999) warrants further
investigation.
Negative regulation of Stat3 has also been associated with
activation of mitogen-activated protein kinases (MAPKs), includ-
ing ERKs, JNKs and p38 MAPK, possibly involving suppression of
JAK activity (Sengupta et al, 1998; Bode et al, 1999; Lim and Cao,
1999; Ahmed and Ivashkiv, 2000; Bode et al, 2001). These
observations, along with recent findings supporting activation of
MAPKs by 15d-PGJ2 in a number of cells (Wilmer et al, 2001;
Lennon et al, 2002), provide another possible explanation for 15d-
PGJ2 effects on Stat3 signalling.
Although the mechanisms by which 15d-PGJ2 causes suppres-
sion of the IL-6-mediated JAK signalling in oral SCC necessitate
further investigation, our findings provide a novel molecular
explanation for the antineoplastic properties of cyclopentenone
prostaglandins, which may facilitate their optimal use as
therapeutic agents.
ACKNOWLEDGEMENTS
This research was supported by grants from PHS/NIH DE13118,
DE12606 and DE014935.
REFERENCES
Ahmed ST, Ivashkiv LB (2000) Inhibition of IL-6 and IL-10 signaling and
Stat activation by inflammatory and stress pathways. J Immunol 165:
5227–5237
Ahn SG, Jeong SY, Rhim H, Kim IK (1998) The role of c-Myc and heat
shock protein 70 in human hepatocarcinoma Hep3B cells during
apoptosis induced by prostaglandin A2/Delta12-prostaglandin J2.
Biochim Biophys Acta 1448: 115–125
Bode JG, Ludwig S, Freitas CA, Schaper F, Ruhl M, Melmed S, Heinrich PC,
Haussinger D (2001) The MKK6/p38 mitogen-activated protein kinase
pathway is capable of inducing SOCS3 gene expression and inhibits IL-6-
induced transcription. Biol Chem 382: 1447–1453
Bode JG, Nimmesgern A, Schmitz J, Schaper F, Schmitt M, Frisch W,
Haussinger D, Heinrich PC, Graeve L (1999) LPS and TNFalpha induce
SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in
macrophages. FEBS Lett 463: 365–370
Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis.
Oncogene 19: 2474–2488
Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109:
1139–1142
Bromberg J, Darnell Jr JE (2000) The role of STATs in transcriptional
control and their impact on cellular function. Oncogene 19: 2468–2473
Bromberg JF (2001) Activation of STAT proteins and growth control.
Bioessays 23: 161–169
Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human
tumors provides novel molecular targets for therapeutic intervention.
Clin Cancer Res 8: 945–954
Butler R, Mitchell SH, Tindall DJ, Young CY (2000) Nonapoptotic cell death
associated with S-phase arrest of prostate cancer cells via the peroxisome
proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-pros-
taglandin J2. Cell Growth Differ 11: 49–61
Chang TH, Szabo E (2000) Induction of differentiation and apoptosis by
ligands of peroxisome proliferator-activated receptor gamma in non-
small cell lung cancer. Cancer Res 60: 1129–1138
Chen Z, Colon I, Ortiz N, Callister M, Dong G, Pegram MY, Arosarena O,
Strome S, Nicholson JC, Van Waes C (1998) Effects of interleukin-1alpha,
interleukin-1 receptor antagonist, and neutralizing antibody on proin-
flammatory cytokine expression by human squamous cell carcinoma
lines. Cancer Res 58: 3668–3676
Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW,
Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S,
Quezado M, Herscher LL, Van Waes C (1999) Expression of
proinflammatory and proangiogenic cytokines in patients with head
and neck cancer. Clin Cancer Res 5: 1369–1379
Clay CE, Atsumi GI, High KP, Chilton FH (2001) Early de novo
gene expression is required for 15-deoxy-Delta 12,14-prostaglandin
J2-induced apoptosis in breast cancer cells. J Biol Chem 276:
47131–47135
Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP (2002) 15-Deoxy-
delta12,14-prostaglandin J2-induced apoptosis does not require PPAR-
gamma in breast cancer cells. J Lipid Res 43: 1818–1828
Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE,
Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH (1999) Influence of J
series prostaglandins on apoptosis and tumorigenesis of breast cancer
cells. Carcinogenesis 20: 1905–1911
Darnell Jr JE (1997) STATs and gene regulation. Science 277: 1630–1635
De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B (2000) JAK2 tyrosine
kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated
protein kinase (MAPK) and signal transducer and activator of
transcription (STAT) pathways and induces apoptosis in myeloma cells.
Br J Haematol 109: 823–828
Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE,
Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A,
Kraker A, Jove R (2001) Constitutive activation of Stat3 by the Src and
JAK tyrosine kinases participates in growth regulation of human breast
carcinoma cells. Oncogene 20: 2499–2513
Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS,
Tweardy DJ (1998) Requirement of Stat3 but not Stat1 activation for
epidermal growth factor receptor-mediated cell growth in vitro. J Clin
Invest 102: 1385–1392
Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S,
Johnson DE, Huang L, He Y, Kim JD (2000) Constitutive activation of
Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in
vivo. Proc Natl Acad Sci USA 97: 4227–4232
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G,
Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling
and its regulation. Biochem J 374: 1–20
Hsiang CH, Straus DS (2002) Cyclopentenone causes cell cycle arrest and
represses cyclin D1 promoter activity in MCF-7 breast cancer cells.
Oncogene 21: 2212–2226
Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS, Mitchell MD (1999)
15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome
proliferator-activated receptor-gamma, induces apoptosis in JEG3
choriocarcinoma cells. Biochem Biophys Res Commun 262: 579–585
Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL,
Xi S, Grandis JR (2002) STAT3 activation abrogates growth factor
dependence and contributes to head and neck squamous cell carcinoma
tumor growth in vivo. Cell Growth Differ 13: 355–362
Kim IK, Lee JH, Sohn HW, Kim HS, Kim SH (1993) Prostaglandin A2 and
delta 12-prostaglandin J2 induce apoptosis in L1210 cells. FEBS Lett 321:
209–214
15d-PGJ2 inhibits IL-6-mediated JAK activation
H Siavash et al
1079
British Journal of Cancer (2004) 91(6), 1074–1080 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yKondo M, Oya-Ito T, Kumagai T, Osawa T, Uchida K (2001) Cyclopente-
none prostaglandins as potential inducers of intracellular oxidative
stress. J Biol Chem 276: 12076–12083
Lennon AM, Ramauge M, Dessouroux A, Pierre M (2002) MAP kinase
cascades are activated in astrocytes and preadipocytes by 15-deoxy-
Delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone
through peroxisome proliferator activator receptor gamma-independent
mechanisms involving reactive oxygenated species. J Biol Chem 277:
29681–29685
Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall
TE, Grandis JR (2002) Differential function of STAT5 isoforms in head
and neck cancer growth control. Oncogene 21: 2846–2853
Levy DE (1999) Physiological significance of STAT proteins: investigations
through gene disruption in vivo. Cell Mol Life Sci 55: 1559–1567
Li L, Shaw PE (2002) Autocrine-mediated activation of STAT3 corre-
lates with cell proliferation in breast carcinoma lines. J Biol Chem 277:
17397–17405
Li L, Tao J, Davaille J, Feral C, Mallat A, Rieusset J, Vidal H, Lotersztajn S
(2001) 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of
human hepatic myofibroblasts. A pathway involving oxidative stress
independently of peroxisome-proliferator-activated receptors. J Biol
Chem 276: 38152–38158
Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of
Stat3 by JNK. J Biol Chem 274: 31055–31061
Liu JD, Lin SY, Ho YS, Pan S, Hung LF, Tsai SH, Lin JK, Liang YC (2003)
Involvement of c-jun N-terminal kinase activation in 15-deoxy-
delta12,14-prostaglandin J2-and prostaglandin A1-induced apoptosis in
AGS gastric epithelial cells. Mol Carcinog 37: 16–24
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder
JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM (1996)
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature
379: 645–648
Ni Z, Lou W, Leman ES, Gao AC (2000) Inhibition of constitutively
activated Stat3 signaling pathway suppresses growth of prostate cancer
cells. Cancer Res 60: 1225–1228
Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T, Dobson P,
Svejgaard A, Odum N (1997) Constitutive activation of a slowly
migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490
inhibits Stat3 activation and growth of mycosis fungoides tumor cell
lines. Proc Natl Acad Sci USA 94: 6764–6769
Nikitakis NG, Siavash H, Hebert C, Reynolds MA, Hamburger AW, Sauk JJ
(2002) 15-PGJ2, but not thiazolidinediones, inhibits cell growth, induces
apoptosis, and causes downregulation of Stat3 in human oral SCCa cells.
Br J Cancer 87: 1396–1403
Ondrey FG, Dong G, Sunwoo J, Chen Z, Wolf JS, Crowl-Bancroft CV,
Mukaida N, Van Waes C (1999) Constitutive activation of transcription
factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck
squamous cell carcinoma cell lines that express pro-inflammatory and
pro-angiogenic cytokines. Mol Carcinog 26: 119–129
Park EJ, Park SY, Joe EH, Jou I (2003) 15d-PGJ2 and rosiglitazone suppress
Janus kinase-STAT inflammatory signaling through induction of
suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol
Chem 278: 14747–14752
Rane SG, Reddy EP (2002) JAKs, STATs and Src kinases in hematopoiesis.
Oncogene 21: 3334–3358
Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB (1998) Rapid inhibition of
interleukin-6 signaling and Stat3 activation mediated by mitogen-
activated protein kinases. Proc Natl Acad Sci USA 95: 11107–11112
Song JI, Grandis JR (2000) STAT signaling in head and neck cancer.
Oncogene 19: 2489–2495
Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind
JS (2003) Epidermal growth factor receptor-independent constitutive
activation of STAT3 in head and neck squamous cell carcinoma is
mediated by the autocrine/paracrine stimulation of the interleukin
6/gp130 cytokine system. Cancer Res 63: 2948–2956
Starr R, Hilton DJ (1998) SOCS: suppressors of cytokine signalling. Int J
Biochem Cell Biol 30: 1081–1085
Starr R, Hilton DJ (1999) Negative regulation of the JAK/STAT pathway.
Bioessays 21: 47–52
Straus DS, Glass CK (2001) Cyclopentenone prostaglandins: new insights
on biological activities and cellular targets. Med Res Rev 21: 185–210
Turkson J, Jove R (2000) STAT proteins: novel molecular targets for cancer
drug discovery. Oncogene 19: 6613–6626
Wilmer WA, Dixon C, Lu L, Hilbelink T, Rovin BH (2001) A
cyclopentenone prostaglandin activates mesangial MAP kinase indepen-
dently of PPARgamma. Biochem Biophys Res Commun 281: 57–62
Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, Kamens
J, Grandis JR (2003) Src kinases mediate STAT growth pathways
in squamous cell carcinoma of the head and neck. J Biol Chem 278:
31574–31583
Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A,
Krolewski JJ, Medveczky P, Jove R (2000) Activation of Stat3 in v-Src-
transformed fibroblasts requires cooperation of Jak1 kinase activity.
J Biol Chem 275: 24935–24944
15d-PGJ2 inhibits IL-6-mediated JAK activation
H Siavash et al
1080
British Journal of Cancer (2004) 91(6), 1074–1080 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y